Two years ago this week, Biogen Idec relaunched Tysabri, the multiple sclerosis and Crohn's disease treatment, after a safety scare. Now, the drug is shaping up to be a blockbuster, the Wall Street Journal reports.

Tysabri was recalled in 2005 after three patients developed a rare brain infection [1] and two died. FDA let the drug back on the market the next year under a monitoring program. Just two years later, Tysabri is expected to surpass $1 billion in annual sales, according to Biogen CEO James Mullen. First-quarter sales were $160 million, and second-quarter numbers will be announced tomorrow.

- read the WSJ article [2]

Related Articles:
No new PML cases for Tysabri [3]
Watchdog endorses use of Tysabri for severe MS [4]
After reintroduction, Tysabri builds patient base [5]
FDA allows Tysabri back on market [6]